Bio Path Holdings Inc (BPTH)

[blairsoldman]

As an old investor (both by age and by length of time in this mess) I seldom bother to check to see what is going on; when you've been 200:1 buggered what is the point? (yes, that is a whine, live with it). However I took a look today to see if the world is any closer to a cancer cure and was disappointed that the BPTH web site is three years or more out of date; it refers to:

A second study in relapsed and refractory AML patients is expected to be initiated in 2017.
and:
- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.
and:
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.

I took a quick look at the 2020 slide show :

http://www.biopathholdings.com/wp-content/uploads/2020/01/BPTH_Corp_Presentation_Jan_2020.pdf

and the results on slide 8 9 10 are what I remember (no I didn't verify) from 2017


I remember the halcion days of 2016 and 2017, it seems the company hasn't moved on since then!!! Does anyone know if they are even still working on this or are they just sitting with their thumbs up their bums enjoying a free ride until the money runs out?

Just asking.